APTX - Aptinyx Inc.
| Previous Close | 4.0200 |
| Open | 4.0400 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 900 |
| Day's Range | 4.0100 - 4.1200 |
| 52 Week Range | 2.8800 - 30.0000 |
| Volume | 92,729 |
| Avg. Volume | 193,471 |
| Market Cap | 136.676M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6920 |
| Earnings Date | Nov 11, 2019 - Nov 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
- Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) for violations of securities laws. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
- ACCESSWIRE
ONGOING SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 13, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 11, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- Zacks
Will Aptinyx Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Aptinyx.
- ACCESSWIRE
IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 9, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. (“Aptinyx” or “the Company”) (NASDAQ: APTX) for violations of securities laws. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
- GlobeNewswire
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Rachel Sherman, M.D., M.P.H., former principal deputy commissioner of the U.S. Food and Drug Administration (FDA), to the company’s Board of Directors, effective immediately. “Rachel’s expertise in drug development, evaluation, and regulation is unparalleled and we are honored to welcome her to our Board of Directors,” stated Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. “During her extraordinary tenure at the FDA, across various divisions and senior-level roles, Rachel has been instrumental in many efforts that have led to remarkable improvements in drug development.
- Zacks
Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft
Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft
- Zacks
How Young Investors Find the Next Google
Sometimes stock ideas and trends can present themselves in unlikely places. If you're paying attention.
- GlobeNewswire
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. The product candidate demonstrated positive recovery of performance on affective and spatial learning tasks that was impaired in a preclinical model of repeat closed head injury. In biomarker readings, NYX-458 also restored neuroendocrine function following disruption due to repeat closed head injury.
- Benzinga
Aptinyx Represents Untapped Value, BMO Says
Aptinyx Inc (NASDAQ: APTX ) reported second-quarter results ahead of expectations and expressed confidence in its cash lasting into 2021. The company has an ongoing Phase 2 study and is progressing towards ...
- Zacks
Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.77% and -2.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS.
- Benzinga
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
- Simply Wall St.
Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
- GlobeNewswire
Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019
EVANSTON, Ill., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Monday, August 12 2019, at 8:00 A.M. ET to report second quarter 2019 financial results and to discuss recent business highlights. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
- Zacks
Aptinyx's Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Aptinyx.
- GlobeNewswire
Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal, Ph.D., the company’s chief scientific officer, will be retiring from his position with the company and focusing on his academic work as a professor at Northwestern University. Dr. Moskal will continue his close association with Aptinyx in a senior advisory capacity. “Joe has been working in brain research for decades and is a true pioneer in NMDA receptor pharmacology,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.
- GlobeNewswire
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and relapse-like behavior in multiple models of alcohol use disorder. “Given the increasingly recognized societal impact of substance abuse, and the lack of safe and effective therapies, we are very encouraged by the activity demonstrated by NYX-783 in these preclinical models of alcohol use disorder,” said Cassia Cearley, Ph.D., vice president of research at Aptinyx.
- GlobeNewswire
Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief business officer, will present at the 2019 BMO Prescription for Success Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
- GlobeNewswire
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive top-line results from a 23-patient, single-blind, sequential design Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with fibromyalgia. Administration of NYX-2925 resulted in statistically significant effects on the primary endpoint, brain activity biomarkers associated with central pain processing, measured using advanced imaging techniques.
- Simply Wall St.
Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful?
Every investor in Aptinyx Inc. (NASDAQ:APTX) should be aware of the most powerful shareholder groups. Institutions...
